Literature DB >> 26412427

Proteomic analysis of hepatocellular carcinoma HepG2 cells treated with platycodin D.

Jin-Jian Lu1, De-Zhao Lu2, Yu-Fei Chen2, Ya-Ting Dong2, Jun-Ren Zhang2, Ting Li3, Zheng-Hai Tang3, Zhen Yang2.   

Abstract

Platycodin D (PD), a triterpenoid saponin isolated from Platycodonis Radix, is a famous Chinese herbal medicine that has been shown to have anti-proliferative effects in several cancer cell lines. The aim of this study was to determine the changes in cellular proteins after the treatment of hepatocellular carcinoma HepG2 cells with PD using proteomics approaches. The cell viability was determined using the MTT assay. The proteome was analyzed by two-dimensional difference gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Western blot analysis was used to confirm the expression of changed proteins. Our results showed that PD inhibited the proliferation of HepG2 cells in concentration- and time-dependent manners. Sixteen proteins were identified to be up-regulated in PD-treated HepG2 cells, including ATP5H, OXCT1, KRT9, CCDC40, ERP29, RCN1, ZNF175, HNRNPH1, HSP27, PA2G4, PHB, BANF1, TPM3, ECH1, LGALS1, and MYL6. Three proteins (i.e., RPS12, EMG1, and KRT1) decreased in HepG2 cells after treatment with PD. The changes in HSP27 and PHB were further confirmed by Western blotting. In conclusion, our results shed new lights on the mechanisms of action for the anti-cancer activity of PD.
Copyright © 2015 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2-D DIGE; HepG2; Platycodin D; Proteome

Mesh:

Substances:

Year:  2015        PMID: 26412427     DOI: 10.1016/S1875-5364(15)30065-0

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  8 in total

1.  Prohibitin regulates mTOR pathway via interaction with FKBP8.

Authors:  Jiahui Zhang; Yanan Yin; Jiahui Wang; Jingjing Zhang; Hua Liu; Weiwei Feng; Wen Yang; Bruce Zetter; Yingjie Xu
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

2.  Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics.

Authors:  Zhengyun Liu; Yan Xu; Wanling Zhang; Xinghong Gao; Guo Luo; Hong Song; Jie Liu; Huan Wang
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

Review 3.  Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.

Authors:  Jie Yang; Bin Li; Qing-Yu He
Journal:  Cell Death Dis       Date:  2018-05-21       Impact factor: 8.469

Review 4.  Saponins from Chinese Medicines as Anticancer Agents.

Authors:  Xiao-Huang Xu; Ting Li; Chi Man Vivienne Fong; Xiuping Chen; Xiao-Jia Chen; Yi-Tao Wang; Ming-Qing Huang; Jin-Jian Lu
Journal:  Molecules       Date:  2016-10-05       Impact factor: 4.411

Review 5.  Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities.

Authors:  Jianjian Li; Zhe Ming; Liuyi Yang; Tingxuan Wang; Gaowen Liu; Qing Ma
Journal:  Genes Dis       Date:  2022-04-29

Review 6.  Using omics approaches to dissect the therapeutic effects of Chinese herbal medicines on gastrointestinal cancers.

Authors:  Si-Yi Li; Wei-Jia Wang; Qiu-Yue Li; Peng-Hui Yang; Xin-Long Li; Yan Yan; Yong Yuan; Yi-Bin Feng; Ming Hong
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

7.  Homogenous and Microbeam X-Ray Radiation Induces Proteomic Changes in the Brains of Irradiated Rats and in the Brains of Nonirradiated Cage Mate Rats.

Authors:  Richard Smith; Jiaxi Wang; Colin Seymour; Cristian Fernandez-Palomo; Jennifer Fazzari; Elisabeth Schültke; Elke Bräuer-Krisch; Jean Laissue; Christian Schroll; Carmel Mothersill
Journal:  Dose Response       Date:  2018-01-22       Impact factor: 2.658

8.  Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma.

Authors:  Xing Li; Bing Li; Pixin Ran; Lanying Wang
Journal:  Oncol Lett       Date:  2018-08-21       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.